Busulphan — Competitive Intelligence Brief

Busulphan (Busulphan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

discontinued Matrix metalloproteinase-9 Oncology Small molecule

Target snapshot

Busulphan (Busulphan) — University of Birmingham.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Busulphan TARGET	Busulphan	University of Birmingham	discontinued		Matrix metalloproteinase-9
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
Monocid	CEFONICID		marketed	cefonicid	Matrix metalloproteinase-9	1984-01-01
Dtic-Dome	dacarbazine	Bayer	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01
Cefradex	cefradine	Bristol-Myers Squibb	marketed	cefradine	Matrix metalloproteinase-9	1974-01-01
Busulfex	busulfan	Waylis	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
flucloxacillin	flucloxacillin	Karlstad University	marketed		Matrix metalloproteinase-9, Androgen receptor, Penicillin-binding protein 1A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.